Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Eisai Inc.
Merck Sharp & Dohme LLC
SWOG Cancer Research Network
Exelixis
Pfizer
Incyte Corporation
Bristol-Myers Squibb
Bristol-Myers Squibb
NRG Oncology
Merck Sharp & Dohme LLC
Novartis
Bristol-Myers Squibb
Telix Pharmaceuticals (Innovations) Pty Limited
Hoffmann-La Roche
AVEO Pharmaceuticals, Inc.
Nektar Therapeutics
Hoffmann-La Roche
Bristol-Myers Squibb
National Cancer Institute (NCI)
Exelixis
Novartis
SFJ Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Heidelberg Pharma AG
Alliance for Clinical Trials in Oncology
Heidelberg Pharma AG
Novartis
Hoffmann-La Roche
Pfizer
GlaxoSmithKline
Novartis
Bayer
INSYS Therapeutics Inc
Bayer
GlaxoSmithKline
Pfizer
Novartis
Pfizer
Pfizer